Program
Anti-CD25 Antibody-drug Conjugate PF-08046032
In Pfizer’s pipeline, CD25V directed antibody-drug conjugate
. Its studies are mostly in Lymphoma, T-Cell, Peripheral, led by Pfizer.
Furthest: phase 1, since Feb 24, 20251 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 10 open or running | phase 1since Feb 24, 2025 | Feb 24, 2025 | none ahead |
- Named in Pfizer’s own pipeline as
PF-08046032
, phase 1, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2025First study: phase 1 study in Lymphoma, T-Cell, PeripheralFirst studyNCT06870487 · 6 enrolled · United States, Spain
TargetBeta
“CD25V directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a detuned-affinity monoclonal antibody directed against CD25 (interleukin-2 receptor subunit alpha; IL-2R alpha; IL-2Ra), conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. U…”NCIt, read by Claude
Other programs on IL2RA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Interleukin-2rule | chiron-corporation | phase 4 | 11 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06870487Lymphoma, T-Cell, Peripheral · United States, Spain | 1 | Terminated | Apr 23, 2026 | 6 |
How it is read
Names in the registry
- “PF-08046032”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, Peripheral, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.